Valuation Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited
Equities
600329
CNE000001808
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 40.70 CNY | -1.09% |
|
-1.02% | -10.78% |
| Mar. 31 | Tianjin Pharmaceutical Da Ren Tang's Attributable Profit Drops 4.4% in 2025 | MT |
| Mar. 31 | Singapore Shares Remain in Red Amid Soaring Energy Costs; Rex International Plunges 20% | MT |
Company Valuation: Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 19,473 | 18,246 | 22,121 | 20,699 | 30,778 | 27,647 | - |
| Change | - | -6.3% | 21.24% | -6.43% | 48.69% | -10.17% | - |
| Enterprise Value (EV) | 19,473 | 18,246 | 22,121 | 20,699 | 30,778 | 27,647 | 27,647 |
| Change | - | -6.3% | 21.24% | -6.43% | 48.69% | -10.17% | 0% |
| P/E ratio | 31.4x | 26.2x | 26.3x | 10.6x | 16.5x | 27.9x | 25.3x |
| PBR | - | 3.45x | 3.93x | 3.02x | - | - | - |
| PEG | - | 2.4x | 1.7x | 0x | -3.68x | -0.6x | 2.5x |
| Capitalization / Revenue | - | 2.21x | 2.69x | 2.83x | 6.26x | 5.17x | 4.77x |
| EV / Revenue | - | 0x | 0x | 0x | 0x | 5.17x | 4.77x |
| EV / EBITDA | - | - | - | - | - | - | - |
| EV / EBIT | - | 0x | 0x | 0x | 0x | 21.3x | 19.4x |
| EV / FCF | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | 1.12 | 1.28 | - | - | - | - |
| Rate of return | - | 3.85% | 3.8% | - | - | - | - |
| EPS 2 | 1 | 1.11 | 1.28 | 2.9 | 2.77 | 1.46 | 1.61 |
| Distribution rate | - | 101% | 100% | - | - | - | - |
| Net sales 1 | - | 8,249 | 8,222 | 7,307 | 4,917 | 5,348 | 5,797 |
| EBITDA | - | 1,099 | 906.4 | - | - | - | - |
| EBIT 1 | - | 980 | 1,097 | 2,567 | 2,490 | 1,295 | 1,426 |
| Net income 1 | 769.1 | 861.8 | 986.7 | 2,229 | 2,131 | 1,124 | 1,239 |
| Net Debt | - | - | - | - | - | - | - |
| Reference price 2 | 31.41 | 29.10 | 33.65 | 30.80 | 45.62 | 40.70 | 40.70 |
| Nbr of stocks (in thousands) | 773,443 | 773,443 | 770,158 | 770,158 | 770,094 | 770,094 | - |
| Announcement Date | 3/30/22 | 3/31/23 | 3/29/24 | 3/28/25 | 3/30/26 | - | - |
1CNY in Million2CNY
Estimates
P/E ratio, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 27.88x | - | - | - | 4.06B | |
| 17.48x | 2.12x | 13.75x | 5.08% | 14.47B | |
| 28.41x | 1.57x | 10.45x | 1.45% | 5.58B | |
| 17.52x | 3.57x | 11.36x | 5.7% | 5.09B | |
| 23.18x | - | - | 1.56% | 4.09B | |
| 15.9x | 2.12x | 9.46x | 2.84% | 3.12B | |
| 15.18x | 2.74x | 11.7x | 5.2% | 1.74B | |
| Average | 20.79x | 2.42x | 11.34x | 3.64% | 5.45B | |
| Weighted average by Cap. | 20.57x | 2.30x | 12.16x | 3.96% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Equities
- 600329 Stock
- Valuation Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited
Select your edition
All financial news and data tailored to specific country editions
